Skip to main content

Sudden Cardiac Arrest

0
Pipeline Programs
7
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Philips
PhilipsNetherlands - Amsterdam
3 programs
12 lead ElectrocardiogramN/A1 trial
HeartStart FRXN/A1 trial
HeartStart HS1N/A1 trial
Active Trials
NCT05636332Completed60Est. Nov 2022
NCT04250857Recruiting1,400Est. Dec 2027
NCT04840797Recruiting1,400Est. Dec 2027
Medtronic
MedtronicNJ - Phillipsburg
2 programs
EP referred groupN/A
ICD or CRT-D DeviceN/A
Rhythm Pharmaceuticals
2 programs
EP referred groupN/A1 trial
ICD or CRT-D DeviceN/A1 trial
Active Trials
NCT03715790Completed1,491Est. May 2021
NCT02099721Completed4,222Est. Sep 2018
Element Biosciences
Element BiosciencesCA - San Diego
2 programs
Jewel Patch Wearable Cardioverter DefibrillatorN/A1 trial
Jewel Patch Wearable Cardioverter DefibrillatorN/A1 trial
Active Trials
NCT05490459Completed18Est. Apr 2024
NCT05201495Completed322Est. Nov 2023
Element Science
Element ScienceCA - San Francisco
2 programs
Jewel Patch Wearable Cardioverter DefibrillatorN/A
Jewel Patch Wearable Cardioverter DefibrillatorN/A
Kestra Medical Technologies
1 program
DefibrillationN/A1 trial
Active Trials
NCT05135403Recruiting5,179Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Philips12 lead Electrocardiogram
Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator
Kestra Medical TechnologiesDefibrillation
PhilipsHeartStart HS1
PhilipsHeartStart FRX
Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator
Rhythm PharmaceuticalsEP referred group
Rhythm PharmaceuticalsICD or CRT-D Device

Clinical Trials (8)

Total enrollment: 14,092 patients across 8 trials

NCT05636332Philips12 lead Electrocardiogram

The Intrepid Clinical Engineering Study

Start: Oct 2022Est. completion: Nov 202260 patients
N/ACompleted
NCT05201495Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator

The Jewel IDE Study

Start: Jan 2022Est. completion: Nov 2023322 patients
N/ACompleted
NCT05135403Kestra Medical TechnologiesDefibrillation

ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)

Start: Nov 2021Est. completion: Oct 20255,179 patients
N/ARecruiting
NCT04840797PhilipsHeartStart HS1

HeartStart HS1 Defibrillator* Event Registry

Start: Feb 2021Est. completion: Dec 20271,400 patients
N/ARecruiting
NCT04250857PhilipsHeartStart FRX

HeartStart FRx Defibrillator Event Registry

Start: Nov 2019Est. completion: Dec 20271,400 patients
N/ARecruiting
NCT05490459Element BiosciencesJewel Patch Wearable Cardioverter Defibrillator

Jewel Electrophysiology (EP) Lab Study

Start: Nov 2018Est. completion: Apr 202418 patients
N/ACompleted
NCT03715790Rhythm PharmaceuticalsEP referred group

Improve SCA Bridge Study

Start: Nov 2018Est. completion: May 20211,491 patients
N/ACompleted
NCT02099721Rhythm PharmaceuticalsICD or CRT-D Device

Improve Sudden Cardiac Arrest Study

Start: Mar 2014Est. completion: Sep 20184,222 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 14,092 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.